RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GC Biopharma Stock

GC Biopharma Net Income 2025

GC Biopharma Net Income

44.79 B KRW

Ticker

006280.KS

ISIN

KR7006280002

In 2025, GC Biopharma's profit amounted to 44.79 B KRW, a 461.31% increase from the 7.98 B KRW profit recorded in the previous year.

The GC Biopharma Net Income history

YEARNET INCOME (undefined KRW)
2026e70.12
2025e44.79
2024e7.98
2023-26.63
202265.45
2021123.21
202081.05
2019-3.64
201834.43
201753.25
201662.97
201594.97
201483.95
201370.07
201253.64
201155.37
2010113.69
200980.52
200848.87
200744.36
200634.79
200529.13
20046.78

GC Biopharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into GC Biopharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GC Biopharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GC Biopharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of GC Biopharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into GC Biopharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing GC Biopharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GC Biopharma’s growth potential.

GC Biopharma Revenue, EBIT and net profit per share

DateGC Biopharma RevenueGC Biopharma EBITGC Biopharma Net Income
2026e2.02 T undefined120.84 B undefined70.12 B undefined
2025e1.86 T undefined96.98 B undefined44.79 B undefined
2024e1.72 T undefined60.51 B undefined7.98 B undefined
20231.63 T undefined34.44 B undefined-26.63 B undefined
20221.71 T undefined81.26 B undefined65.45 B undefined
20211.54 T undefined73.66 B undefined123.21 B undefined
20201.5 T undefined50.25 B undefined81.05 B undefined
20191.36 T undefined41.68 B undefined-3.64 B undefined
20181.33 T undefined50.15 B undefined34.43 B undefined
20171.29 T undefined90.3 B undefined53.25 B undefined
20161.2 T undefined78.45 B undefined62.97 B undefined
20151.05 T undefined91.68 B undefined94.97 B undefined
2014975.33 B undefined96.97 B undefined83.95 B undefined
2013888.17 B undefined78.81 B undefined70.07 B undefined
2012811.77 B undefined74.36 B undefined53.64 B undefined
2011767.91 B undefined85.39 B undefined55.37 B undefined
2010793.05 B undefined153.05 B undefined113.69 B undefined
2009643.21 B undefined119.39 B undefined80.52 B undefined
2008516.1 B undefined67.93 B undefined48.87 B undefined
2007442.3 B undefined58.45 B undefined44.36 B undefined
2006405.12 B undefined54.86 B undefined34.79 B undefined
2005372.37 B undefined33.96 B undefined29.13 B undefined
2004141.98 B undefined5.02 B undefined6.78 B undefined

GC Biopharma stock margins

The GC Biopharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GC Biopharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GC Biopharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the GC Biopharma's sales revenue. A higher gross margin percentage indicates that the GC Biopharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the GC Biopharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the GC Biopharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GC Biopharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GC Biopharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GC Biopharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

GC Biopharma Margin History

GC Biopharma Gross marginGC Biopharma Profit marginGC Biopharma EBIT marginGC Biopharma Profit margin
2026e29.79 %5.99 %3.47 %
2025e29.79 %5.21 %2.41 %
2024e29.79 %3.53 %0.47 %
202329.79 %2.12 %-1.64 %
202234 %4.75 %3.82 %
202133.85 %4.79 %8.01 %
202029.29 %3.34 %5.39 %
201927.42 %3.07 %-0.27 %
201825.91 %3.76 %2.58 %
201728.48 %7.01 %4.13 %
201629.39 %6.55 %5.26 %
201532.35 %8.75 %9.06 %
201431.84 %9.94 %8.61 %
201330.95 %8.87 %7.89 %
201231.24 %9.16 %6.61 %
201133.71 %11.12 %7.21 %
201040.6 %19.3 %14.34 %
200941.94 %18.56 %12.52 %
200839.57 %13.16 %9.47 %
200740.79 %13.21 %10.03 %
200640.64 %13.54 %8.59 %
200536.09 %9.12 %7.82 %
200433.2 %3.54 %4.78 %

GC Biopharma Aktienanalyse

What does GC Biopharma do?

GC Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding GC Biopharma's Profit Margins

The profit margins of GC Biopharma represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of GC Biopharma's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating GC Biopharma's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

GC Biopharma's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When GC Biopharma’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about GC Biopharma stock

How much profit has GC Biopharma made this year?

GC Biopharma has made 44.79 B KRW this year.

How has the profit developed compared to last year?

The profit has increased by 461.31% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does GC Biopharma publish its earnings?

GC Biopharma publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of GC Biopharma?

The profits of GC Biopharma are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of GC Biopharma?

You can learn more about the earnings of GC Biopharma by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does GC Biopharma pay?

Over the past 12 months, GC Biopharma paid a dividend of 1,500 KRW . This corresponds to a dividend yield of about 1.03 %. For the coming 12 months, GC Biopharma is expected to pay a dividend of 1,555.91 KRW.

What is the dividend yield of GC Biopharma?

The current dividend yield of GC Biopharma is 1.03 %.

When does GC Biopharma pay dividends?

GC Biopharma pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of GC Biopharma?

GC Biopharma paid dividends every year for the past 22 years.

What is the dividend of GC Biopharma?

For the upcoming 12 months, dividends amounting to 1,555.91 KRW are expected. This corresponds to a dividend yield of 1.07 %.

In which sector is GC Biopharma located?

GC Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von GC Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GC Biopharma from 5/1/2024 amounting to 1,500 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did GC Biopharma pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of GC Biopharma in the year 2024?

In the year 2024, GC Biopharma distributed 1,500 KRW as dividends.

In which currency does GC Biopharma pay out the dividend?

The dividends of GC Biopharma are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GC Biopharma

Our stock analysis for GC Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GC Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.